PFS improved with cabozantinib + nivolumab + ipilimumab for patients with previously untreated advanced renal cell carcinoma<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, Sept. 26, 2022 (HealthDay News) — Triplet therapy of cabozantinib + nivolumab + ipilimumab significantly improves progression-free survival (PFS) compared with placebo + nivolumab + ipilimumab for patients with previously untreated advanced renal cell carcinoma (aRCC) of intermediate or poor risk, according to a study presented at the annual meeting of the European Society for Medical Oncology, held from Sept. 9 to 13 in Paris.<\/p>\n
Toni Choueiri, M.D., from the Dana-Farber Cancer Institute in Boston, and colleagues conducted a randomized phase 3 study involving previously untreated patients with clear cell aRCC of International Metastatic RCC Database Consortium intermediate or poor risk. A total of 855 patients were randomly assigned to receive cabozantinib or matched placebo; both treatment groups also received nivolumab and ipilimumab for four cycles, followed by nivolumab for up to two years.<\/p>\n
The researchers found that the study met the primary PFS end point (hazard ratio, 0.73); median PFS was not reached for the triplet therapy and was 11.3 months for placebo + nivolumab + ipilimumab. The objective response rate was 43 and 36 percent for the triplet therapy and placebo + nivolumab + ipilimumab groups, respectively; the median duration of response was not reached in either group. Grade 3\/4 treatment-related adverse events occurred in 73 and 41 percent of those receiving triplet therapy and placebo + nivolumab + ipilimumab, respectively.<\/p>\n
“The initial findings provide a clear look at the efficacy and safety profile of this triplet therapy and demonstrate a significant progression-free survival benefit,” Choueiri said in a statement.<\/p>\n
Several authors disclosed financial ties to biopharmaceutical companies, including Exelixis, which manufactures cabozantinib and funded the study.<\/p>\n
Abstract<\/a><\/p>\n